Galera Therapeutics (GRTX) Competitors $0.02 +0.00 (+7.11%) As of 08/21/2025 09:38 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. SBFM, CDIO, JBIO, PLRZ, LIAN, ENSC, NKGN, APLM, PPBT, and GNPXShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Sunshine Biopharma (SBFM), Cardio Diagnostics (CDIO), Jade Biosciences (JBIO), Polyrizon (PLRZ), LianBio (LIAN), Ensysce Biosciences (ENSC), NKGen Biotech (NKGN), Apollomics (APLM), Purple Biotech (PPBT), and Genprex (GNPX). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors Sunshine Biopharma Cardio Diagnostics Jade Biosciences Polyrizon LianBio Ensysce Biosciences NKGen Biotech Apollomics Purple Biotech Genprex Galera Therapeutics (NASDAQ:GRTX) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Which has more volatility and risk, GRTX or SBFM? Galera Therapeutics has a beta of 1.91, meaning that its share price is 91% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Which has better earnings and valuation, GRTX or SBFM? Sunshine Biopharma has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.19-0.13Sunshine Biopharma$34.87M0.19-$5.13M-$150.88-0.01 Do analysts recommend GRTX or SBFM? Sunshine Biopharma has a consensus target price of $15.00, suggesting a potential upside of 948.22%. Given Sunshine Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Galera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sunshine Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer GRTX or SBFM? In the previous week, Galera Therapeutics' average media sentiment score of 0.00 equaled Sunshine Biopharma'saverage media sentiment score. Company Overall Sentiment Galera Therapeutics Neutral Sunshine Biopharma Neutral Do institutionals and insiders hold more shares of GRTX or SBFM? 50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 0.1% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is GRTX or SBFM more profitable? Galera Therapeutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -17.35%. Galera Therapeutics' return on equity of 0.00% beat Sunshine Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Sunshine Biopharma -17.35%-26.04%-20.72% SummarySunshine Biopharma beats Galera Therapeutics on 7 of the 13 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.82M$870.55M$5.80B$9.60BDividend YieldN/A4.84%3.84%4.08%P/E Ratio-0.071.1430.4025.20Price / SalesN/A25.72455.95115.56Price / CashN/A19.5637.1558.42Price / Book-0.016.629.006.24Net Income-$59.08M-$4.93M$3.26B$265.30M7 Day PerformanceN/A1.62%0.67%-0.84%1 Month PerformanceN/A2.60%3.41%-1.53%1 Year PerformanceN/A11.77%29.23%17.73% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.02+7.1%N/A-63.4%$1.82MN/A-0.0730Gap DownSBFMSunshine Biopharma2.1526 of 5 stars$1.42-3.4%$15.00+956.3%-52.6%$6.48M$34.87M-0.013CDIOCardio Diagnostics2.6522 of 5 stars$3.63-2.4%$60.00+1,552.9%-72.4%$6.32M$40K0.001Earnings ReportShort Interest ↑JBIOJade Biosciences2.2584 of 5 stars$7.36-1.9%$16.00+117.4%N/A$6.18MN/A-0.2420Positive NewsAnalyst RevisionPLRZPolyrizonN/A$1.03flatN/AN/A$6.17MN/A0.00N/ALIANLianBioN/A$0.06flatN/A-81.5%$6.16MN/A-0.07110Gap UpENSCEnsysce Biosciences0.4067 of 5 stars$2.03-4.7%N/A-66.4%$6.03M$5.21M-0.5010NKGNNKGen BiotechN/A$0.13-5.4%N/A-83.7%$5.96MN/A-0.03N/ANegative NewsGap DownAPLMApollomics0.0649 of 5 stars$5.40-5.2%N/A-53.8%$5.94M$1.49M0.0045Positive NewsGap UpPPBTPurple Biotech1.4994 of 5 stars$2.27flat$33.00+1,353.7%N/A$5.88MN/A-5.4020Gap DownGNPXGenprex1.5143 of 5 stars$0.17-10.9%N/A-79.6%$5.64MN/A0.0020Earnings ReportShort Interest ↑ Related Companies and Tools Related Companies SBFM Competitors CDIO Competitors JBIO Competitors PLRZ Competitors LIAN Competitors ENSC Competitors NKGN Competitors APLM Competitors PPBT Competitors GNPX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access